Detalles de la búsqueda
1.
Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant.
Front Immunol;
14: 1188431, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37435073
2.
Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: a randomised, double-blind, placebo-controlled, phase 2a trial.
Lancet Infect Dis;
23(12): 1360-1369, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37517422
3.
Proficiency tests to evaluate the impact on assay outcomes of harmonized influenza-specific Intracellular Cytokine Staining (ICS) and IFN-É£ Enzyme-Linked ImmunoSpot (ELISpot) protocols.
J Immunol Methods;
523: 113584, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37918618
4.
The role of cell-mediated immunity against influenza and its implications for vaccine evaluation.
Front Immunol;
13: 959379, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36052083
5.
Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine.
Front Immunol;
13: 852904, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35464450
6.
Harmonization and qualification of intracellular cytokine staining to measure influenza-specific CD4+ T cell immunity within the FLUCOP consortium.
Front Immunol;
13: 982887, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36341380
7.
A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine.
Front Immunol;
13: 1021500, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36275772
8.
Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium.
Front Immunol;
13: 984642, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36159843
Resultados
1 -
8
de 8
1
Próxima >
>>